Medications as adjunct therapy for weight loss: Approved and off-label agents in use

Journal of the American Dietetic Association

Volumn 105, Issue 6, 2005, Pages 948-959

  Moyers, Susan B ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; AMFEBUTAMONE; AMFEPRAMONE; AMPHETAMINE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BENZPHETAMINE; CITALOPRAM; EPHEDRA EXTRACT; FLUOXETINE; MAZINDOL; METFORMIN; METHAMPHETAMINE; MIGLITOL; MONOAMINE OXIDASE INHIBITOR; OBEZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE RESIN; PHENTRIDE; PSEUDOEPHEDRINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; TERENINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; ZONISAMIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AGITATION; ANXIETY; BLOATING; BLOOD PRESSURE; BODY MASS; BULIMIA; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EATING DISORDER; FECES INCONTINENCE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART PALPITATION; HEART RATE VARIABILITY; HUMAN; HYPERHIDROSIS; HYPERTENSION; INDIGESTION; INSOMNIA; IRRITABILITY; LANGUAGE DISABILITY; MEMORY DISORDER; MENTAL CONCENTRATION; MIGRAINE; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; OBESITY; PARESTHESIA; PRESCRIPTION; PSYCHOSIS; RASH; RESTLESSNESS; REVIEW; SEIZURE; SIDE EFFECT; SPEECH DISORDER; SWEATING; SYSTEMATIC REVIEW; TACHYCARDIA; TASTE DISORDER; TREATMENT CONTRAINDICATION; TREMOR; URINARY EXCRETION; URINARY FREQUENCY; URTICARIA; VISUAL IMPAIRMENT; VITAMIN BLOOD LEVEL; VOMITING; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 20444499801     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jada.2005.03.010     Document Type: Article

References (72)

1. K.M. Flegal, M.D. Carroll, C.L. Ogden, C.L. Johnson Prevalence and trends in obesity among US adults, 1999-2000 JAMA 288 2002 1723 1727
2. D. Thompson, A.M. Wolf The medical-care cost burden of obesity Obes Rev 2 2001 189 197
3. R. Sturm The effects of obesity, smoking, and drinking on medical problems and costs. Obesity outranks both smoking and drinking in its deleterious effects on health and health costs Health Aff (Millwood) 21 2002 245 253
4. S.J. Bartlett Motivating patients toward weight loss Practical strategies for addressing overweight and obesity Physician Sports Med 31 2003 29 38
5. J. Vidal Updated review on the benefits of weight loss Int J Obes suppl 4 2002 S25 S28
6. L.F. Van Gaal, M.A. Wauters, I.H. De Leeuw The beneficial effects of modest weight loss on cardiovascular risk factors Int J Obes Relat Metab Disord 21 suppl 1 1997 S5 S9
7. A. Scheen Current management strategies for coexisting diabetes mellitus and obesity Drugs 63 2003 1165 1184
8. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, D.M. Nathan Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
9. V.J. Stevens, E. Obarzanek, N.R. Cook, I.M. Lee, L.J. Appel, D. Smith West, N.C. Milas, M. Mattfeldt-Beman, L. Belden, C. Bragg, M. Millstone, J. Raczynski, A. Brewer, B. Singh, J. Cohen Long-term weight loss and changes in blood pressure Results of the Trials of Hypertension Prevention, phase II Ann Intern Med 134 2001 1 11
10. G. Oster, D. Thompson, J. Edelsberg, A. Bird, G. Colditz Lifetime health and economic benefits of weight loss among obese persons Am J Public Health 89 1999 1536 1542
11. National Heart, Lung, and Blood Institute and National Institute for Diabetes and Digestive and Kidney Diseases. Clinical guidelines on the identification, evaluation, and treatment of obesity. Available at: http://www.nhlbi.nih.gov/guidelines/obesity/obgdlns.htm. Accessed July 5, 2004.
12. L.W. Craighead, A.J. Stunkard, R.M. O'Brien Behavior therapy and pharmacotherapy for obesity Arch Gen Psychiatry 38 1981 736 738
13. D. Ryan Medicating the obese patient Endocrinol Metab Clin North Am 25 1996 989 1004
14. K.M. McTigue, R. Harris, B. Hemphill, L. Lux, S. Sutton, A.J. Bunton, K.N. Lohr Screening and interventions for obesity in adults Summary of the evidence for the US Preventive Services Task Force Ann Intern Med 139 2003 933 949
15. N. Finer Sibutramine Its mode of action and efficacy Intl J Obes 26 suppl 4 2002 S29 S33
16. A. Astrup, S. Toubro When, for whom and how to use sibutramine Int J Obes Relat Metab Disord 25 suppl 4 2001 S2 S7
17. S.J. McNulty, E. Ur, G. Williams A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin Diabetes Care 26 2003 125 131
18. D.E. Arterburn, P.K. Crane, D.L. Veenstra The efficacy and safety of sibutramine for weight loss A systematic review Arch Intern Med 164 2004 994 1003
19. N. Narkiewicz Sibutramine and its cardiovascular profile Intl J Obesity 26 suppl 4 2002 S38 S41
20. Anorexiants D.J. Cada Drug Facts and Comparisons 2002 Pocket Version 6th ed. 2001 Facts and Comparisons St Louis, MO 428 431
21. M.H. Davidson, J. Hauptman, M. DiGirolamo, J.P. Foreyt, C.H. Halsted, D. Heber, D.C. Heimburger, C.P. Lucas, D.C. Robbins, J. Chung, S.B. Heymsfield Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat A randomized controlled trial JAMA 281 1999 235 242
22. J.R. McDuffie, K.A. Calis, S.L. Booth, G.I. Uwaifo, J.A. Yanovski Effects of orlistat on fat-soluble vitamins in obese adolescents Pharmacotherapy 22 2002 814 822
23. D.E. Kelley, L.H. Kuller, T. McKolanis, P. Harper, J. Mancino, S. Kalhan Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes Diabetes Care 27 2004 33 40
24. D.E. Kelley, G.A. Bray, F.X. Pi-Sunyer, S. Klein, J. Hill, J. Miles, P. Hollander Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes Diabetes Care 25 2002 1033 1041
25. J.M. Miles, L. Leiter, P. Hollander, T. Wadden, J.W. Anderson, M. Doyle, J. Foreyt, L. Aronne, S. Klein Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin Diabetes Care 25 2002 1123 1128
26. M. Hanefeld, G. Sachse The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes A randomized, placebo-controlled trial Diabetes Obes Metab 4 2002 415 423
27. M. Tiikkainen, R. Bergholm, A. Rissanen, A. Aro, I. Salminen, M. Tamminen, K. Teramo, H. Yki-Jarvinen Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women Am J Clin Nutr 79 2004 22 30
28. D. Arterburn, P.H. Noel Extracts from Clinical Evidence BMJ 322 2001 1406 1409
29. S. O'Meara, R. Riemsma, L. Shirran, L. Mather, G. ter Riet A systematic review of the clinical effectiveness of orlistat used for the management of obesity Obes Rev 5 2004 51 68
30. D. Hansen, A. Astrup, S. Toubro, N. Finer, P. Kopelman, J. Hilsted, S. Rossner, W. Saris, L. VanGaal, W. James, M. Goulder Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity Results from the European multi-centre STORM trial Int J Obes 25 2002 496 501
31. W.P. James, A. Astrup, N. Finer, J. Hilsted, P. Kopelman, S. Rossner, W.H. Saris, L.F. Van Gaal Effect of sibutramine on weight maintenance after weight loss A randomized trial Lancet 356 2000 2119 2125
32. J.S. Torgerson, J. Hauptman, M.N. Boldrin, L. Sjostrom XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients Diabetes Care 27 2004 155 161
33. M.A. van Baak, E. van Mil, A.V. Astrup, N. Finer, L.F. Van Gaal, J. Hilsted, P.G. Kopelman, S. Rössner, W.P. James, W.H.M. Saris Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial) Am J Clin Nutr 78 2003 209 214
34. R. Padwal, S.K. Li, D.C. Lau Long-term pharmacotherapy for overweight and obesity A systematic review and meta-analysis of randomized controlled trials Int J Obes Relat Metab Disord 27 2003 1437 1446
35. G.F. Bray, F.L. Greenway Current and potential drugs for treatment of obesity Endocrine Rev 20 1999 805 875
36. Medscape drug info. Available at: http://www.medscape.com/druginfo. Accessed March 1, 2004.
37. R.H.G. McKay Long-term use of diethylproprion in obesity Curr Med Res Opin 1 1973 489 493
38. J.T. Silverstone, T. Solomon The long-term management of obesity in general practice Br J Clin Pract 19 1965 395 398
39. J.A. Fernández-López, X. Remesar, M. Foz, M. Alemany Pharmacological approaches for the treatment of obesity Drugs 62 2002 915 944
40. A. Lee, J.E. Morley Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes Obes Res 6 1998 47 53
41. A. Fontbonne, M.A. Charles, I. Juhan-Vague, J.M. Bard, P. Andre, F. Isnard, J.M. Cohen, P. Grandmottet, P. Vague, M.E. Safar, E. Eschwege The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution (BIGPRO trial) Diabetes Care 19 1996 920 926
42. C.J. Glueck, R.N. Fontaine, P. Wang, M.T. Subbiah, K. Weber, E. Illig, P. Streicher, L. Sieve-Smith, T.M. Tracy, J.E. Lang, P. McCullough Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30 Metabolism 50 2001 856 861
43. D. Giugliano, A. Quatraro, G. Consoli, A. Minei, A. Ceriello, N. De Rosa, F. D'Onofrio Metformin for obese, insulin-treated diabetic patients Improvement in glycaemic control and reduction of metabolic risk factors Eur J Clin Pharmacol 44 1993 107 112
44. A. Gokcel, Y. Gumurdulu, H. Karakose, E. Melek Ertorer, N. Tanaci, N. BascilTutuncu, N. Guvener Evaluation of the safety and efficacy of sibutramine, orlistat, and metformin in the treatment of obesity Diabetes Obes Metab 4 2002 49 55
45. T.M. Wolever, J.L. Chiasson, R.G. Josse, J.A. Hunt, C. Palmason, N.W. Rodger, S.A. Ross, E.A. Ryan, M.H. Tan Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes Int J Obes Relat Metab Disord 21 1997 756 763
46. A. Lee, P. Patrick, J. Wishart, M. Horowitz, J.E. Morley The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics Diabetes Obes Metab 4 2002 329 335
47. F. Bayraktar, F. Hamulu, A.G. Ozgen, C. Yilmaz, M. Tuzun, T. Kabalak Acarbose treatment in obesity A controlled study Eat Weight Disord 3 1998 46 49
48. H. Hauner, D. Petzinna, B. Sommerauer, H. Toplak Effect of acarbose on weight maintenance after dietary weight loss in obese subjects Diabetes Obes Metab 3 2001 423 427
49. E. Ben-Menachem, M. Axelsen, E.H. Johanson, A. Stagge, U. Smith Predictors of weight loss in adults with topiramate-treated epilepsy Obes Res 11 2003 556 562
50. S.L. McElroy, L.M. Arnold, N.A. Shapira, P.E. Keck Jr, N.R. Rosenthal, M.R. Karim, M. Kamin, J.I. Hudson Topiramate in the treatment of binge eating disorder associated with obesity A randomized, placebo-controlled trial Am J Psychiatry 160 2003 255 261
51. N.A. Shapira, T.D. Goldsmith, S.L. McElroy Treatment of binge-eating disorder with topiramate A clinical case series J Clin Psychiatry 61 2000 368 372
52. J.W. Winkelman Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate Sleep Med 4 2003 243 246
53. G. Bray, P. Hollander, S. Klein, R. Kushner, B. Levy, M. Fitchet, B.H. Perry A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity Obes Res 11 2003 722 733
54. A. Astrup Effect of long-term topiramate on body weight maintenance after weight loss induced by a low-calorie diet in obese subjects 2003 Abstract 1702-P, American Diabetes Association 63rd Scientific Sessions, New Orleans, LA, June
55. K.M. Gadde, D.M. Franciscy, H.R. Wagner 2nd, K.R. Krishnan Zonisamide for weight loss in obese adults A randomized controlled trial JAMA 289 2003 1820 1825
56. S.L. McElroy, R. Kotwal, J.I. Hudson, E.B. Nelson, P.E. Keck Zonisamide in the treatment of binge-eating disorder An open-label, prospective trial J Clin Psychiatry 65 2004 50 56
57. N. Harto-Truax, W.C. Stern, L.L. Miller, T.L. Sato, A.E. Cato Effects of bupropion on body weight J Clin Psychiatry 44 1983 183 186
58. E.C. Settle Jr Bupropion Update 1993 Int Drug Ther News 28 1993 29 36
59. A.K. Jain, R.A. Kaplan, K.M. Gadde, T.A. Wadden, D.B. Allison, E.R. Brewer, R.A. Leadbetter, N. Richard, B. Haight, B.D. Jamerson, K.S. Buaron, A. Metz Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms Obes Res 10 2002 1049 1056
60. J.W. Anderson, F.L. Greenway, K. Fujioka, K.M. Gadde, J. McKenney, P.M. O'Neil Bupropion SR enhances weight loss A 48-week double-blind, placebo-controlled trial Obes Res 10 2002 633 641
61. K.M. Gadde, C.B. Parker, L.G. Maner, H.R.I.I. Wagner, E.J. Logue, M.K. Drezner, K.R.R. Krishnan Bupropion for weight loss An investigation of efficacy and tolerability in overweight and obese women Obes Res 9 2001 544 551
62. J.C. Appolinarion, S.L. McElroy Pharmacological approaches in the treatment of binge eating disorder Curr Drug Targets 5 2004 301 307
63. D. Michelson, J.D. Amsterdam, F.M. Quitkin, F.W. Reimherr, J.F. Rosenbaum, J. Zajecka, K.L. Sundell, Y. Kim, C.M. Beasley Jr Changes in weight during a 1-year trial of fluoxetine Am J Psychiatry 156 1999 1170 1176
64. S.Z. Yanovski, J.A. Yanovski Drug therapy Obesity N Engl J Med 346 2002 591 602
65. D. Arterburn, P.H. Noel Obesity BMJ 322 2001 1406 1409
66. C.K. Haddock, W.S. Poston, P.L. Dill, J.P. Foreyt, M. Ericsson Pharmacotherapy for obesity A quantitative analysis of four decades of published randomized clinical trials Int J Obes 26 2002 262 273
67. S.L. Norris, X. Zhang, A. Avenell, E. Gregg, C.H. Schmid, C. Kim, J. Lau Efficacy of pharmacotherapy for weight loss in adults with Type 2 diabetes mellitus A meta-analysis Arch Intern Med 164 2004 1395 1404
68. American Gastroenterological Association American Gastroenterological Association medical position statement on obesity Gastroentereology 123 2002 879 881
69. H. Nawaz, D.L. Katz American College of Preventive medicine practice policy statement. Weight management counseling of overweight adults Am J Prev Med 21 2001 73 78
70. R.F. Kushner Roadmaps for Clinical Practice: Case studies in Disease Prevention and Health Promotion-Assessment and Management of Adult Obesity: A Primer for Physicians. 2003 American Medical Association Chicago, IL
71. AACE/ACE Position Statement on the Prevention, Diagnosis and Treatment of Obesity 1998 American Association of Clinical Endocrinologists Jacksonville, FL
72. W.S.C. Poston, J.P. Foreyt Successful management of the obese patient Am Fam Phys 61 2000 3615 3652